Clinical Trials Browser

Completed × INDUSTRY × Neoplasm, Residual × Clear all

Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Neoplasm, Residual

NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Phase 3 Completed

511 enrolled 26 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT01207388 2020-02-10

BLAST

Phase 2 Completed

116 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00560794 2015-01-26

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

21 enrolled 19 charts

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

AMPLIFY-201

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

BLAST

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)